Nevada Medicaid and Nevada Check Up News (Third Quarter 2024 Provider Newsletter) [Read]

Attention Behavioral Health Providers: Monthly Behavioral Health Training Assistance (BHTA) Webinar Scheduled [See Web Announcement 2009]

Attention All Providers: Requirements on When to Use the National Provider Identifier (NPI) of an Ordering, Prescribing or Referring (OPR) Provider on Claims [Announcement 850]

If you are a Medicaid provider whose revalidation application has not been processed by your termination due date, you will be ineligible to provide services to any Nevada Medicaid or Nevada Check Up recipients, including both Fee-for-Service and Managed Care Organization (MCO) enrolled recipients. See Web Announcement 1265

Enrollment Termination Frequently Asked Questions (FAQs) [Review]

Notifications

Unwinding COVID-19 Information

Known System Issues-Click HERE

Paper claims are no longer accepted by Nevada Medicaid. Please refer to Web Announcement 1733 and Web Announcement 1829 for additional information.

Top 10 Claim Denial Reasons and Resolutions/Workarounds for November 2024 Professional Claims. See Web Announcement 3509.

Top Enrollment Return Reasons and Resolutions for January 2024 Submissions. See Web Announcement 3350.

Top Prior Authorization Denial Reasons for the Third Quarter of 2024. See Web Announcement 3488.

Attention Providers Using the Authorization Criteria Function: Results that return prior authorization (PA) requirements are accurate. For results that return “There are no records found based on the search criteria,” there may be a PA requirement if limits have been exceeded. To verify PA requirements, please refer to the Medicaid Services Manual (MSM) Chapter for your service type at dhcfp.nv.gov and the Billing Guide for your provider type at www.medicaid.nv.gov.

Scheduled Site Maintenance

During the scheduled site maintenance window the Provider Web Portal will be unavailable. The table below shows the regularly scheduled maintenance window. All times will be in the Pacific time zone.

Monday - Friday
12:00AM - 12:30AM

Monday
8:00PM - 12:00AM

Notice Date Title
December 2017 For Review at December 7, 2017, Meeting: Anti-inflammatory Agents – Misc., Topical
December 2017 For Review at December 7, 2017, Meeting: Beta Agonist and Anticholinergic Combinations
December 2017 For Review at December 7, 2017, Meeting: Hepatitis C Direct-Acting Antivirals
December 2017 For Review at December 7, 2017, Meeting: Inhaled Steroids
December 2017 For Review at December 7, 2017, Meeting: Irritable Bowel Syndrome and Constipation Agents
December 2017 For Review at December 7, 2017, Meeting: Ophthalmic Antihistamines
December 2017 For Review at December 7, 2017, Meeting: Opioids, Long Acting
December 2017 For Review at December 7, 2017, Meeting: Topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
September 2017 For Review at September 28, 2017, Meeting: Angiotensin II Receptor Blockers (ARBs) Single Entity Agents
September 2017 For Review at September 28, 2017, Meeting: Anticoagulants, Injectable
September 2017 For Review at September 28, 2017, Meeting: Anticoagulants, Oral
September 2017 For Review at September 28, 2017, Meeting: Anticonvulsants
September 2017 For Review at September 28, 2017, Meeting: Antidepressants, Other
September 2017 For Review at September 28, 2017, Meeting: Antiemetics
September 2017 For Review at September 28, 2017, Meeting: Antivirals, Influenza
September 2017 For Review at September 28, 2017, Meeting: Attention-Deficit/Hyperactivity Disorder (ADHD) Agents
September 2017 For Review at September 28, 2017, Meeting: Atypical Antipsychotics
September 2017 For Review at September 28, 2017, Meeting: Beta Agonist and Corticosteroid Combinations
September 2017 For Review at September 28, 2017, Meeting: Biguanides
September 2017 For Review at September 28, 2017, Meeting: Bone Density Regulators
September 2017 For Review at September 28, 2017, Meeting: Calcium Channel Blocking Agents (Dihydropyridines)
September 2017 For Review at September 28, 2017, Meeting: Calcium Channel Blocking Agents (Non-Dihydropyridines)
September 2017 For Review at September 28, 2017, Meeting: Cardiovascular, Angiotensin II Receptor Blockers (ARBs) – Combination Products
September 2017 For Review at September 28, 2017, Meeting: Cholesterol Absorption Inhibitors
September 2017 For Review at September 28, 2017, Meeting: Epinephrine Products for Anaphylaxis
September 2017 For Review at September 28, 2017, Meeting: Fluoroquinolones
September 2017 For Review at September 28, 2017, Meeting: Growth Hormone
September 2017 For Review at September 28, 2017, Meeting: Immunomodulators
September 2017 For Review at September 28, 2017, Meeting: Incretin Mimetics & Amylinomimetics
September 2017 For Review at September 28, 2017, Meeting: Inflammatory Bowel Disease Agents
September 2017 For Review at September 28, 2017, Meeting: Insulin and Incretin Mimetic Combination Agents
September 2017 For Review at September 28, 2017, Meeting: Intranasal Antihistamines
September 2017 For Review at September 28, 2017, Meeting: Intranasal Corticosteroids
September 2017 For Review at September 28, 2017, Meeting: Leukotriene Modifiers
September 2017 For Review at September 28, 2017, Meeting: Multiple Sclerosis Agents
September 2017 For Review at September 28, 2017, Meeting: Ophthalmic Antibiotic Steroid Combinations
September 2017 For Review at September 28, 2017, Meeting: Ophthalmic Antibiotics and Combinations
September 2017 For Review at September 28, 2017, Meeting: Opioids, Long Acting
September 2017 For Review at September 28, 2017, Meeting: Platelet Aggregation Inhibitors
September 2017 For Review at September 28, 2017, Meeting: Proton Pump Inhibitors
September 2017 For Review at September 28, 2017, Meeting: Pulmonary Arterial Hypertension Agents
September 2017 For Review at September 28, 2017, Meeting: Scabicides and Pediculicides
September 2017 For Review at September 28, 2017, Meeting: Sodium-Glucose Cotransporter 2 Inhibitors
September 2017 For Review at September 28, 2017, Meeting: Statins (HMG-CoA Reductase Inhibitors)
June 2017 For Review at June 22, 2017, Meeting: Anti-inflammatory Agents – Misc., Topical
June 2017 For Review at June 22, 2017, Meeting: Beta Agonist and Anticholinergic Combinations
June 2017 For Review at June 22, 2017, Meeting: Cardiovascular, Angiotensin II Receptor Blockers (ARBs) – Combination Products
June 2017 For Review at June 22, 2017, Meeting: Cholesterol Absorption Inhibitors
June 2017 For Review at June 22, 2017, Meeting: Insulin and Incretin Mimetic Combination Agents
June 2017 For Review at June 22, 2017, Meeting: Irritable Bowel Syndrome and Constipation Agents
June 2017 For Review at June 22, 2017, Meeting: Ophthalmic Antihistamines
June 2017 For Review at June 22, 2017, Meeting: Opioids, Long Acting
June 2017 For Review at June 22, 2017, Meeting: Sodium-glucose Co-transporter 2 Inhibitors
March 2017 For Review at March 23, 2017, Meeting: Atypical Antipsychotics
March 2017 For Review at March 23, 2017, Meeting: Beta Agonists
March 2017 For Review at March 23, 2017, Meeting: Insulins
March 2017 For Review at March 23, 2017, Meeting: Ophthalmic Immunomodulators
March 2017 For Review at March 23, 2017, Meeting: Pulmonary Arterial Hypertension Agents
March 2017 For Review at March 23, 2017, Meeting: Sodium-Glucose Co-transporter 2 Inhibitors